.jpg) A vial of FakhraVac | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | Fakhra, MIVAC |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status |
|
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
FAKHRAVAC (Persian:واکسن فخرا) is aCOVID-19 vaccine developed inIran by theOrganization of Defensive Innovation and Research,[1] a subsidiary ofIran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reachingclinical trials.[1][2][3] It is currently inphase III.[4][5] It received emergency use authorization in Iran on 9 September 2021.[4]
The vaccine is named after the Iranian nuclear scientistMohsen Fakhrizadeh.[1] According to the Iranian authorities, he was working on a vaccine in response to theCOVID-19 pandemic in Iran.[1][6] Fakhrizadeh was assassinated in November 2020 inan attack Iran and US intelligence attributed to Israel.[1][7]
It requires two doses given byintramuscular injection 3 weeks apart.[5]
FAKHRAVAC is aninactivated virus-based vaccine.[3]
In August 2021, production capacity of the vaccine was reported to be 1 million dose per month and was planned to be "multiplied in a few months ".[4] In October 2021, the production was reported to be stopped amid Iran's growing vaccine imports.[8] In January 2022, the Director General of Health of the Ministry of Defense announced that the first shipment (around 462,000 doses) of the vaccine had been delivered to the Iranian Ministry of Health.[9]
| Phase | Registration number | Start | Number of participants | Age of participants | ||
|---|---|---|---|---|---|---|
| Total | Vaccine | Control | ||||
| I | IRCT20210206050259N1Archived 28 April 2021 at theWayback Machine | 8 March 2021 | 135 | 96? | 39?(placebo) | 18–55 years |
| II | IRCT20210206050259N2Archived 16 June 2021 at theWayback Machine | 8 June 2021 | 500 | 250 | 250(placebo) | 18–70 years |
| III | IRCT20210206050259N3Archived 7 September 2021 at theWayback Machine | 29 August 2021 | 41,128 | 20,564 | 20,564(Sinopharm BIBP vaccine) | >18 years |
FAKHRAVAC received emergency use authorization in Iran on 9 September 2021.[4] In October 2021, Iran's Food and Drug Administration was considering giving full authorization to the vaccine for third/booster dose.[8]
